With the negative view on ISIS today, a favorable vote by the panel tomorrow could rocket the stock towards the $45-$60 range based on $300,000 per year per patient, a patient population of 6,000 and a total market therefore of $1.8B/year.
With 25M shares outstanding, that $1.8B equates to $72/share. Now not all patients will go on the medication, but these are the numbers we are dealing with. Therefore a $45-$60/share target price is very reasonable and a share price below that makes a buyout compelling.
It has to get the FDA panel vote first, so we have to wait and see what happens tomorrow. While it looks favorable, it isn't done yet. So one step at a time.